Does doxycycline protect against development of clostridium difficile infection?

Clinical Infectious Diseases

Volumn 55, Issue 5, 2012, Pages 615-620

  Doernberg, Sarah B ^a   Winston, Lisa G ^a   Deck, Daniel H ^a   Chambers, Henry F ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; MACROLIDE; METRONIDAZOLE; PENICILLIN G; PENICILLIN G DERIVATIVE; QUINOLONE DERIVATIVE; VANCOMYCIN;

ADULT; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFTRIAXONE; CLOSTRIDIUM DIFFICILE; COHORT STUDIES; DOXYCYCLINE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84864953708     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis457     Document Type: Article

References (33)

1. Dubberke E, Butler A, Yokoe D, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Cont Hosp Ep 2010; 31:1030-7. Available at: http://dx.doi.org/10.1086/656245. Accessed 10 December 2011.
2. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis 2009; 48:568-76. Available at: http://dx.doi.org/10.1086/596703. Accessed 10 December 2011.
3. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359:1932-40.
4. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile- related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-9.
5. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142:624-31.
6. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-31.
7. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9. Available at: http://dx.doi.org/10.1056/NEJMoa051639. Accessed 10 December 2011. (Pubitemid 41770165)
8. Kyne L, Hamel M, Polavaram R, Kelly C. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-53. Available at: http://dx.doi.org/10.1086/338260. Accessed 10 December 2011. (Pubitemid 34062235)
9. Thomas C, Stevenson M, Riley TV. Antibiotics and hospitalacquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemoth 2003; 51:1339-50.
10. Baxter R, Ray G, Fireman B. Case-Control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Cont Hosp Ep 2008; 29:44-50. Available at: http://dx.doi.org/10.1086/ 524320. Accessed 10 December 2011. (Pubitemid 351267773)
11. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40:1-15.
12. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 162:678-684. Available at: http://www.jstor.org/stable/30131701. Accessed 10 December 2011.
13. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004; 7:59-62.
14. Thamlikitkul V, Danpakdi K, Chokloikaew S. Incidence of diarrhea and Clostridium difficile toxin in stools from hospitalized patients receiving clindamycin, beta-lactams, or nonantibiotic medications. J Clin Gastroenterol 1996; 22:161-3.
15. Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 2008; 168:2254-60.
16. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9:730-3.
17. Thomas C, Stevenson M, Williamson D, Riley T. Clostridium difficile- associated diarrhea: epidemiological data from western Australia associated with a modified antibiotic policy. Clin Infect Dis 2002; 35:1457-62. Available at: http://dx.doi.org/10.1086/342691. Accessed 10 December 2011. (Pubitemid 36020687)
18. Norén T, Alriksson I, Åkerlund T, Burman LG, Unemo M. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infec 2010; 16:1104-10.
19. Robbins M, Marais R, Felmingham D, Ridgway GL. The in-vitro activity of doxycycline and minocycline against anaerobic bacteria. J Antimicrob Chemoth 1987; 20:379-82.
20. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51:2716-9.
21. Herpers B, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48:1732-5. Available at: http ://dx.doi.org/10.1086/599224. Accessed 10 December 2011.
22. Golledge CL, Riley TV. Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis. Lancet 1995; 345:1377-8.
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9.
24. McDonald L, Coignard B, Dubberke E, Song X, Horan T, Kutty P. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Cont Hosp Ep 2007; 28:140-5. Available at: http://dx.doi.org/10.1086/ 511798. Accessed 10 December 2011. (Pubitemid 46374153)
25. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69:239-241. Available at: http://www.jstor.org/stable/ 2335876. Accessed 10 December 2011.
26. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(suppl 2):S27-72.
27. Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med 1997; 157:1421-8.
28. Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis 2011; 52:1451-7.
29. Rothman K, Greenland S, Lash T. Modern epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2008.
30. Kuntz J, Yang M, Cavanaugh J, Saftlas A, Polgreen P. Trends in Clostridium difficile infection among peripartum women. Infect Cont Hosp Ep 2010; 31:532-4. Available at: http://www.jstor.org/stable/10.1086/652454. Accessed 10 December 2011.
31. Zarzaur BL, Croce MA, Fabian TC, Fischer P, Magnotti LJ. A population- based analysis of neighborhood socioeconomic status and injury admission rates and in-hospital mortality. J Am Coll Surg 2010; 211:216-23.
32. Cubbin C, LeClere FB, Smith GS. Socioeconomic status and the occurrence of fatal and nonfatal injury in the United States. Am J Public Health 2000; 90:70-7.
33. Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61:157-62.